


**Precision Delivery in Cancers of the Liver:**  
Clinical Data Shows Improved Targeting  
with the Surefire Infusion System

# 68%

Surefire increases tumor coverage compared to a microcatheter by a mean of 68%.<sup>1,2</sup> ( $p < 0.05$ )


## Change in Tumor Dose



# 58%

Surefire reduces dose delivered to healthy tissue by a mean of 58% compared to a microcatheter.<sup>1,3</sup> ( $p < 0.05$ )

## Change in Dose to Healthy Tissue



<sup>1</sup> A. Pasciak, et al. "The Impact of an Antireflux Catheter on Target Volume Particle Distribution in Liver-Directed Embolotherapy: A Pilot Study", *J Vasc Interv Radiol* 2015; 26:660-669.

<sup>2</sup> Increased tumor deposition was also noted in all patients, ranging from a factor of 1.33 to a factor of 1.90 (mean, 1.68;  $\sigma=0.20$ ), representing a relative increase of 33%-90%. *J Vasc Interv Radiol* 2015; 26:660-669.

<sup>3</sup> Decreases in hepatic nontarget embolization were found in all patients when the antireflux catheter was used. These decreases ranged from a factor of 0.11 to a factor of 0.76 (mean, 0.42;  $\sigma=0.19$ ), representing a 24%-89% reduction. *J Vasc Interv Radiol* 2015; 26:660-669.

